The total return over the past 12 months is -11.93% vs. +16.94% for the S&P 500. So far it's up -47.52% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (11.93%) | (19.33%) | (25.06%) | N/A | N/A | N/A |
| Total Return CAGR | (11.93%) | (19.33%) | (25.06%) | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Gain Therapeutics, Inc. (GANX)
| Year | Start price | End price | GANX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $3.22 | $1.69 | (47.52%) | +14.51% | (62.03%) |
| 2025 | $2.16 | $3.22 | +49.07% | +17.72% | +31.35% |
| 2024 | $3.27 | $2.16 | (33.94%) | +24.89% | (58.83%) |
| 2023 | $3.13 | $3.27 | +4.47% | +26.19% | (21.72%) |
| 2022 | $5.43 | $3.13 | (42.36%) | (18.17%) | (24.19%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
